Premium
Clopidogrel: A Case for Indication‐Specific Pharmacogenetics
Author(s) -
Johnson J A,
Roden D M,
Lesko L J,
Ashley E,
Klein T E,
Shuldiner A R
Publication year - 2012
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2012.21
Subject(s) - clopidogrel , medicine , cyp2c19 , conventional pci , percutaneous coronary intervention , pharmacogenetics , clinical pharmacology , adverse effect , pharmacology , cardiology , genotype , myocardial infarction , biology , cytochrome p450 , metabolism , gene , biochemistry
The CYP2C19*2 loss‐of‐function allele is associated with reduced generation of active metabolites of clopidogrel. However, meta‐analyses have supported or discounted the impact of genotype on adverse cardiovascular outcomes during clopidogrel therapy, depending on studies included in the analysis. Here we review these data and conclude that evidence supports a differential effect of genotype on protection from major adverse cardiovascular outcomes following percutaneous coronary intervention (PCI), but not for other clopidogrel indications. Clinical Pharmacology & Therapeutics (2012); 91 5, 774–776. doi: 10.1038/clpt.2012.21